Login to Your Account

Omeros What They 'Knee'-ded: Mixed Phase III, New Trial Due

By Randy Osborne
Staff Writer

Wednesday, January 2, 2013
Equivocal results from its first pivotal Phase III trial with OMS103HP in knee surgery shaved Omeros Corp.'s stock, but gave the company a roadmap for the next study, which will use postoperative pain – a secondary endpoint, met in the latest experiment – as the primary outcome goal.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription